| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
NervGen Pharma Corp.$1.73
+0.06 (+3.29%)
D 23Pipeline Score Richly Valued Pharma · Clinical
Market Cap
168.34 M
EPS
-0.40
P/E Ratio
-
Value Trade
2.21 M
-45.97 %
Week
-47.21 %
1 Month
-51.4 %
3 Month
-66.98 %
6 Month
-66.98 %
5 Year
-66.98 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
190.70 K
52 Week Range
2.02 - 6.30
% held by Insiders
21.92 %
% held by Institutions
2.1 %
Enterprise Value
156.47 M
Total Shares
79.29 M
Short %
6.52 %
Float Shares
62.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NervGen Pharma Corp.
35Total events
2Upcoming
3Tier-1 (high impact)
2025 – 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T3Enrollment Update
Subscribe to view catalyst details
Event history 2
TBD
◆Trial InitiationNVG-291Trial
Subscribe to view catalyst details
TBD
◆Timing GuidanceNVG-291Presentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D23
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 22%
Micro Cap (rank 713 of 913)
Percentile RankNervGen Pharma Corp. faces pipeline headwinds (23/100), with $126M risk-adjusted pipeline value, led by NVG-291 in Spinal Cord Injury (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVG-291 Small molecule | Spinal Cord Injuries | Phase 1 | NCT05965700 | 12% | $126M | COMPLETED | 24 | SLOW | B (69) | Jan 21, 2026 | MODERATE_RISK | MEDIUM Jul 16, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NVG-291 Fast TrackOrphan | chronic tetraplegia | Phase 1b/2a | 2026-05-26 | p=0.0197; 100% (10/10) of NVG-291 subjects were classified as responders; 10% (1/10) of placebo subjects (p=0.0001) Read More | NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study Read More | |
NVG-291 Fast TrackOrphan | chronic tetraplegia | Phase 1b/2a | 2026-05-26 | p=0.0197; 100% (10/10) of NVG-291 subjects were classified as responders; 10% (1/10) of placebo subjects (p=0.0001) Read More | NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study Read More | |
NVG-291 Fast TrackOrphan | chronic tetraplegia | Phase 1b/2a | 2026-05-26 | p=0.0197; 100% (10/10) of NVG-291 subjects were classified as responders; 10% (1/10) of placebo subjects (p=0.0001) Read More | NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NGEN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NGEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NGENNervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
NervGen Pharma announced positive results from the Phase 1b/2a CONNECT SCI study, showing that NVG-291 significantly improves gait quality and promotes genuine neural recovery in chronic tetraplegia. The study found that all subjects receiving NVG-291 responded positively, contrasting sharply with placebo results. These findings support NVG-291's potential as a first-in-class therapy for spinal cord injury.
Read more →NGEN▼ -43.5%on this newsshared move
NervGen Announces Proposed Public Offering of Securities
NervGen Pharma Corp. has announced a public offering of common shares and warrants to fund the clinical advancement of its lead therapeutic candidate, NVG-291. The offering is subject to customary closing conditions and will utilize proceeds for clinical studies and corporate purposes. Leerink Partners and TD Cowen are managing the offering, which complies with relevant securities regulations.
Read more →NGEN▼ -43.5%on this newsshared move
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
NervGen Pharma Corp. has announced a public offering of 24 million common shares priced at $2.50 each, aiming to raise approximately $60 million. The proceeds will be used to advance its lead therapeutic candidate, NVG-291, through clinical studies. The offering is set to close on May 26, 2026, pending customary conditions.
Read more →NGENFORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company NervGen Pharma Corp. (" NervGen " or the " Company ") 112-970 Burrard Street Unit 1290 Vancouver, BC V6Z 2R4 Item 2: Date of Material Change
NervGen Pharma Corp. has announced a public offering of 24 million common shares at $2.50 each, aiming to raise about $60 million for clinical studies on NVG-291 and general corporate expenses. The offering includes warrants for additional shares at an exercise price of $3.68. PFP Biosciences, a company insider, participated in this offering, reflecting a supportive investment stance. The board approved the offering without material dissent, aiming for an expedited closing for business reasons.
Read more →NGENNervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen Pharma Corp. reported its Q1 2026 financial results, highlighting a successful FDA End-of-Phase 2 meeting for its RESTORE study of NVG-291 in chronic tetraplegia. With site activation underway, the study is set to begin in mid-2026. The company also announced leadership changes to bolster its clinical development efforts and reported a net loss of $1.7 million for the quarter.
Read more →NGENCondensed consolidated interim financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars - Unaudited) For the three months ended
NervGen Pharma Corp. released its condensed consolidated interim financial statements for the three months ending March 31, 2026, which show a net loss of $1,675,549. This marks an improvement compared to a loss of $3,948,192 for the same period last year. The company remains in a pre-revenue stage, relying on financing to support its ongoing research and development efforts. Its overall financial position has weakened with a decrease in cash reserves and continued operational losses. The need for additional funding to progress clinical programs remains a significant concern.
Read more →NGENNervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
NervGen Pharma has appointed Dr. Keith Vendola as Chief Financial Officer to enhance its financial strategy and operations. Dr. Vendola brings over two decades of experience in biopharmaceutical finance and strategy. His leadership is expected to support the company's advancement of NVG-291, a potential first-in-class treatment for spinal cord injury.
Read more →NGENNervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
NervGen Pharma Corp. announced its participation in the H.C. Wainwright 'HCW@Home' series and the 2026 Bloom Burton & Co. Healthcare Investor Conference. CEO Adam Rogers and the executive team will represent the company at these events. NervGen is focused on developing neuroreparative therapeutics, particularly for spinal cord injuries, with its lead candidate NVG-291 showing promising results.
Read more →NGEN▼ -9.6%on this news
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
NervGen Pharma has successfully completed an End-of-Phase 2 meeting with the FDA, aligning on the parameters for its upcoming Phase 3 study, RESTORE, which will evaluate NVG-291 for chronic tetraplegia. The study aims to assess improvements in fine-motor hand use and includes various secondary endpoints. Initiation of RESTORE is on track for mid-2026.
Read more →NGENNervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
NervGen Pharma reported its full year 2025 financial results, highlighting significant progress in the development of NVG-291 for chronic tetraplegia. The company completed its End-of-Phase 2 meeting with the FDA and anticipates initiating a Phase 3 study in mid-2026. Additionally, positive results from the CONNECT SCI study were reported, supporting the therapeutic potential of NVG-291. The company plans to expand its clinical indications for NVG-291, with updates expected in mid-2026.
Read more →NGENForm 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer NervGen Pharma Corp. (" NervGen " or the " Company ") 112-970 Burrard Street, Unit 1290 Vancouver, BC V6Z 2R4 Item 2. Date of Material Cha
NervGen Pharma Corp. announced its decision to voluntarily delist its common shares from the TSX Venture Exchange, effective March 16, 2026. This move aims to reduce costs and administrative burdens, facilitating greater focus on clinical execution and shareholder value creation. Despite the delisting, shareholders will retain trading access on Nasdaq, and the company remains a reporting issuer under Canadian securities laws.
Read more →NGEN▲ +8.1%on this news
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
NervGen Pharma has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior VP of Patient Advocacy and Clinical Affairs. These appointments aim to strengthen the company's leadership as it advances NVG-291, a potential treatment for spinal cord injury. Both leaders bring extensive experience in regulatory affairs and patient advocacy, respectively.
Read more →NGENNervGen Pharma to Participate at Upcoming Investor Conferences
NervGen Pharma Corp. announced its participation in several upcoming investor conferences, including the Oppenheimer Healthcare Conference and the TD Cowen Health Care Conference. The company is focused on developing neuroreparative therapeutics for spinal cord injuries, with its lead candidate, NVG-291, showing promising results in clinical trials. The company aims to transform treatments for neurotraumatic conditions.
Read more →NGENNervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
NervGen Pharma Corp. will present at the Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium from February 15-17, 2026, in Washington, DC. The symposium aims to unite the spinal cord injury community and discuss advancements in research and treatment. NervGen's lead therapeutic candidate, NVG-291, has demonstrated durable improvements in patients with chronic spinal cord injury.
Read more →NGENNervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
NervGen Pharma has appointed Adam Rogers as its new CEO, effective immediately. The Board of Directors expressed confidence in his leadership, particularly during his tenure as Interim CEO, which included a successful Nasdaq listing. Dr. Rogers aims to drive the company's mission of developing neuroreparative therapeutics for spinal cord injury, particularly focusing on the late-stage development of NVG-291.
Read more →NGEN▼ -6.9%on this news
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
NervGen Pharma Corp. will ring the Nasdaq closing bell on January 22, 2026, to celebrate its recent listing. The event will feature CEO Adam Rogers and the management team, emphasizing the company's mission to aid spinal cord injury recovery. NervGen's lead candidate, NVG-291, has shown promising results in clinical trials.
Read more →NGENForm 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer NervGen Pharma Corp. (" NervGen " or the " Company ") 112-970 Burrard Street Unit 1290 Vancouver, BC V6Z 2R4 Item 2. Date of Material Chan
NervGen Pharma Corp. has announced that its common shares have been approved for listing on the Nasdaq stock exchange, effective January 8, 2026. The company's shares will trade under the symbol 'NGEN'. This listing represents a pivotal achievement for NervGen, providing them with increased visibility and access to capital markets. The news was disseminated through GlobeNewswire and filed accordingly on SEDAR+.
Read more →Competitive Position
How NGEN ranks across every disease it competes inCompetitive Position is a premium feature
See how NGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial